Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

2013230 citationsJournal Articlehybrid Open Access

Authors

Lisa A. Jackson · Group Health Cooperative

Alejandra Gurtman · Pfizer (United States)

Martin van Cleeff · Triangle

Kathrin U. Jansen · Pfizer (United States)

Deepthi Jayawardene · Pfizer (United States)

Carmel Devlin · Pfizer (United States)

Daniel A. Scott ·

Abstract

PCV13 induces a greater functional immune response than PPSV23 for the majority of serotypes covered by PCV13, suggesting that PCV13 could offer immunological advantages over PPSV23 for prevention of vaccine-type pneumococcal infection.

Topics & Keywords

Pneumonia and Respiratory Infections Bacterial Infections and Vaccines Respiratory viral infections research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Vaccine

Volume 31, Issue 35, pp. 3577-3584

DOI: 10.1016/j.vaccine.2013.04.085

Field-Weighted Citation Impact: 17.15